EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Entera Bio's enterprise value is $68.14 Mil.
Entera Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.84 Mil. Therefore, Entera Bio's EV-to-EBITDA for today is -7.71.
The historical rank and industry rank for Entera Bio's EV-to-EBITDA or its related term are showing as below:
ENTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -13.22 Med: -2.22 Max: -0.02
Current: -7.71
During the past 9 years, the highest EV-to-EBITDA of Entera Bio was -0.02. The lowest was -13.22. And the median was -2.22.
ENTX's EV-to-EBITDA is ranked worse than 100% of 470
companies
in the Biotechnology industry
Industry Median: 9.07
vs ENTX: -7.71
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-18), Entera Bio's stock price is $2.2908.
Entera Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.310. Therefore, Entera Bio's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Entera Bio EV-to-EBITDA Historical Data
The historical data trend for Entera Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Entera Bio Annual Data
Trend
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
-2.08
-1.31
-4.64
-0.68
-1.21
Entera Bio Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
-0.68
-2.01
-1.50
-1.38
-1.21
Competitive Comparison
For the Biotechnology subindustry, Entera Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Entera Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Entera Bio's EV-to-EBITDA falls into.
Entera Bio EV-to-EBITDA Calculation
Entera Bio's EV-to-EBITDA for today is calculated as:
Entera Bio's current Enterprise Value is $68.14 Mil.
Entera Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entera Bio (NAS:ENTX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Entera Bio's share price for today is $2.2908.
Entera Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.310.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Entera Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENTX has been successfully added to your 